Article

Updates in the Treatment of Relapsed or Refractory Marginal Zone Lymphoma

This publication reviews the role of Bruton tyrosine kinase inhibitors and PI3K inhibitors, particularly in the relapsed or refractory setting, for the treatment of marginal zone lymphoma, recapping key insights from a scientific interchange & workshop.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
View More
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Video

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Apr 8th 2025 - May 14th 2025

online-activity
View More
Related Content
The Evolving Therapeutic Landscape for Marginal Zone Lymphoma: Expert Perspectives
November 17th 2021

The Evolving Therapeutic Landscape for Marginal Zone Lymphoma: Expert Perspectives